Simplifying Global Compliance
Relistor CRL May Trigger More Safety Concerns With Constipation Drugs
Clinical Trials Advisor
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor most likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say.
To View This Article:
Subscribe To Clinical Trials Advisor
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing